Z4D.SI Medi Lifestyle SES down 8.33% intraday 17 Jan 2026: S$0.012 key support
Z4D.SI stock fell into the top losers list intraday on 17 Jan 2026 after a 1-day decline of 8.33%, trading at S$0.012 on the Singapore Exchange (SES). Volume has been thin today relative to the 50-day average of 982,600 shares, highlighting liquidity risk for small-cap healthcare names. Medi Lifestyle Limited (Z4D.SI) operates postpartum and therapy services under NADORA and Back to Life brands, but weak margins and tight cash metrics are weighing on sentiment. We analyse price action, key ratios and our model forecast to give a short-term outlook for Z4D.SI stock.
Intraday move: Z4D.SI stock price and flow
The immediate fact is price: S$0.012 with a reported 1-day change of -8.33% and a 3-month gain of 10.00%, marking Z4D.SI stock among intraday top losers. Average daily volume is 982,600 but today’s recorded volume is 0, showing erratic trading that increases short-term volatility and execution risk for larger orders.
Fundamentals snapshot: Z4D.SI stock financials and ratios
Medi Lifestyle’s trailing metrics show an EPS of -0.01 and a negative PE, with Price/Sales at 1.03 and book value per share negative at -0.0137. Current ratio sits at 0.52, and working capital is -S$2,242,000, underlining balance-sheet stress and limited short-term liquidity for this Singapore healthcare small cap.
Technical view: Z4D.SI stock support, averages and indicators
Technically, Z4D.SI stock trades near its short-term averages: a 50-day average price of S$0.01062 and 200-day average of S$0.00895, placing today’s S$0.012 above both. Momentum indicators show RSI 63.70 and ADX 42.80 indicating a strong short-term trend, but high MFI 93.98 flags overbought conditions in low-liquidity moves.
Meyka AI rates and forecast for Z4D.SI stock
Meyka AI rates Z4D.SI with a score out of 100: 62.76 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly S$0.010, quarterly S$0.020, and yearly S$0.03986. Compared with the current S$0.012, the model implies a year‑ahead upside of ~232.19% to S$0.0399, while the monthly view implies -16.67% near-term downside. Forecasts are model-based projections and not guarantees.
Catalysts and risks for Z4D.SI stock in Healthcare sector
Upside catalysts include stronger postpartum centre occupancy or a pickup in commodity trading margins; the company’s website lists service expansion across Malaysia and China. Major risks are continued negative margins, tight cash flow, and low trading liquidity; the healthcare sector overall shows modest YTD weakness but positive 1Y momentum, which may limit sector‑driven lifts for Z4D.SI stock.
Valuation and near-term price targets for Z4D.SI stock
Using Meyka AI’s year forecast as a reference, a conservative 12‑month price target is S$0.04, aligned to the model’s S$0.0399 projection; an alternative near-term trading target is S$0.02 if operational improvements appear. Given current market cap S$1,768,827.00 and 160,802,419 shares outstanding, these targets imply high percentage moves and reflect elevated risk.
Final Thoughts
Z4D.SI stock is trading as a small‑cap healthcare laggard on 17 Jan 2026, at S$0.012 and flagged among intraday top losers with a 1‑day drop of 8.33%. Weak fundamentals — negative EPS -0.01, current ratio 0.52, and negative book value per share -0.01366 — increase downside vulnerability. Liquidity is a major practical risk: average volume 982,600 contrasts with thin intraday flow today. Meyka AI’s forecast model projects a year‑end level of S$0.03986, implying an upside of about 232.19% from S$0.012, while a nearer monthly projection of S$0.010 implies a -16.67% decline. Our Meyka grade (62.76, Grade B, HOLD) reflects mixed signals from industry peers, weak cash metrics and potential operational catalysts. Traders should treat Z4D.SI as high‑volatility, speculative exposure: consider tight stops, small position sizing, and monitor upcoming announcements and outpatient occupancy data closely. Forecasts are model‑based projections and not guarantees.
FAQs
What drove the intraday drop in Z4D.SI stock today?
The intraday decline of 8.33% reflects thin trading and profit‑taking in a low‑liquidity stock. Weak fundamentals, negative EPS and tight cash metrics amplified selling pressure. No single headline was recorded; monitor company updates and sector flows for confirmation.
What is Meyka AI’s 12‑month forecast for Z4D.SI stock?
Meyka AI’s yearly projection for Z4D.SI stock is S$0.03986, which implies approximately 232.19% upside from the current S$0.012. This is a model output and not an investment guarantee.
Is Z4D.SI stock a buy for income investors?
No. Medi Lifestyle (Z4D.SI) has no dividend history and current metrics show negative earnings and constrained cash. Income investors should look for stable payout ratios and stronger liquidity elsewhere.
What are the key risks to watch for Z4D.SI stock?
Watch working capital strain (working capital -S$2,242,000), negative margins, erratic trading volume, and any operational softening at NADORA or Back to Life centres. These factors can deepen selling pressure in Z4D.SI stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
